
|Podcasts|February 4, 2022
RWD ‘Fitness’ Steps for Pharma
How FDA’s new guidance on real-world data reshapes critical “fit-for-purpose” evaluations
Advertisement
Matthew W. Reynolds, vice president, real-world solutions, at IQVIA, dives into the implications of FDA’s recent draft guidance on using real-world data from electronic health records and medical claims data to aid in drug development and regulatory decision-making—and shares specific steps pharma companies can take to assess the relevance and quality of their data in light of this guidance.
The latest episode of The Pharmaceutical Commerce Podcast is available directly on SoundCloud.
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
How Specialty Growth and Cold Chain Demand Are Rewriting Distribution Strategy
2
Why Geopolitical Supply Chain Mapping Is Critical for Life Sciences
3
Commercial Trade's Expanding Mandate: From Product Movement to Commercial Performance
4
Mid-Year Check-In: Has Prior Auth Reform Delivered?
5

